Biora Therapeutics Application for Ulcerative Colitis Treatment Gets FDA Clearance
2023年12月1日 - 7:29AM
Dow Jones News
By Denny Jacob
Biora Therapeutics' investigational new drug application for
moderate to severe ulcerative colitis treatment BT-600 was cleared
by the Food and Drug Administration.
Ariella Kelman, chief medical officer of the biotech company,
said Biora will complete activities required by the FDA and trial
site prior to enrolling the first subject in its Phase 1 clinical
trial in the U.S. in the coming weeks.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
November 30, 2023 17:14 ET (22:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Biora Therapeutics (NASDAQ:BIOR)
過去 株価チャート
から 5 2024 まで 6 2024
Biora Therapeutics (NASDAQ:BIOR)
過去 株価チャート
から 6 2023 まで 6 2024